Washington State University INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE

Similar documents
Compounding Questions and Answers

CGMP Requirements for Investigational Products

Nonsterile Compounding: USP and Best Practices for Community Pharmacists

Overview. A brief from

BRIEFING 1168 Compounding for Phase I Investigational Studies,

USP Chapter 823 USP 32 (old) vs. USP 35 (new)

Remote Production of Custom Antibodies

Purdue Animal Care and Use Committee (PACUC) APPLICATION TO USE VERTEBRATE ANIMALS IN RESEARCH, TEACHING, OR TESTING

Leachable and Extractable Testing

Latest USP Initiatives: Monographs, General Chapters, and Compounding

PHYSICO-CHEMICAL, BIOLOGICAL OR MICROBIOLOGICAL TESTS OF MEDICINAL PRODUCTS

HardyVal TM CSP MEDIUM-RISK LEVEL MEDIA-FILL CHALLENGE KITS

Critical Environment Products and Services

Compounding Pharmacy Accreditation Standards. Table of Contents. An Overview of BOC Compounding Pharmacy Accreditation 6/23/2017

Derivation and Justification of Safety Thresholds

Quality is Our Promise.

USP CHAPTER <797> INTRODUCTION RISK LEVELS

Chapter WAC Compounding Practices Crosswalk

Ancillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach

Microbiological Consideration for Non-Sterile Pharmaceutical

GLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE

The GAP Analysis for Nonsterile Compounding

GUIDELINES FOR THE USE OF CONTROLLED SUBSTANCES IN RESEARCH MICHIGAN STATE UNIVERSITY ENVIRONMENTAL HEALTH AND SAFETY

Annex A2. Guidance on Process Validation Scheme for Aseptically Processed Products

Product Permission Document (PPD) of Botulinum Toxin Type A for Injection Ph.Eur Purified Neurotoxin Complex

Vertebrate Animal Use Protocol for Research or Testing

FDA Update on Compounding

September 2, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

Ensuring Quality Pharmacy Compounding: Implications for Pharmaceutics Education

Hot Topics in Drug Product Process Validation: A Reviewer s Perspective

Secundum Artem. USP Chapter <795> Pharmaceutical Compounding - Nonsterile Preparations INTRODUCTION BACKGROUND VOLUME 13 NUMBER 4

Analytical and formulation attributes

Flexible and Pending Monographs

Early Development Best Practices for Stability- Regulatory Perspective

HardyVal TM CSP RANDOM TEST KIT

Expiration Dating of Unit-Dose Repackaged Solid Oral Dosage Form Drug Products Guidance for Industry

Sterile Compounding elearning Course Curriculum 28 lessons with 33 hours of CE. Fundamentals of Sterile Compounding (8 lessons/8 hours CE)

STIMULI TO THE REVISION PROCESS

GUIDELINE FOR THE STABILITY TESTING

Reference Standards for Monoclonal Antibodies: Key Challenges Addressed

Theodore Sullivan Partner Quarles & Brady LLP (Washington, DC)

Republic of the Philippines Department of Health OFFICE OF THE SECRETARY M a n i l a

INNOVATIVE COMPOUNDING SERVICES

Extractables and leachables: An Introduction

for IND and RDRC Regulated PET Compounding

BRIEFING. . Over time, 466 may be used less frequently and may be withdrawn.

Sterile Compounding elearning Course Curriculum 28 lessons with 33 hours of CE. Fundamentals of Sterile Compounding (8 lessons/8 hours CE)

TITLE: Research Pharmacy Standard Policy SOP #: INV-100 Page: 1 of 5 Effective Date: 8/31/17

Introduction to CMC Regulatory Affairs

LUNCH AND LEARN. October 14, CE Activity Information & Accreditation

Pre-Screening revised checklist for BA/BE NOC for Export Purpose

Changes in European Endotoxin Testing Regulations and Guidance By Mick Dawson

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE:

PHARMACY NETWORK. 1st Quarter Newsletter 2016

MINIMUM REQUIREMENTS FOR A VENDOR

Study Summary. Results: All tested media-filled vials were negative for growth of any microorganisms.

GUIDELINES ON THE STABILITY DATA REQUIRED FOR REGISTRATION OF STOCK REMEDIES IN SOUTH AFRICA

Office for Human Subject Protection. University of Rochester

Industry Perspective on Manufacturing in Early Development

Policies Concerning Survival Surgery of Mice

US Regulatory Requirements: Clinical & Clinical Research Production, SPECT & PET Radiopharmaceuticals (RPs)

STANDARD OPERATING PROCEDURES DIVISION OF COMPARATIVE MEDICINE UNIVERSITY OF SOUTH FLORIDA

Responding to an FDA 483

CMC Considerations for 505(b)(2) Applications. Monica Cooper, Ph.D. FDA/CDER/OPS/ONDQA AAPS Annual Meeting Washington, D.C.

OPERATION INTRODUCTION

Orange and Yellow Guides

Pharmaceutical Sciences

Compounding nonsterile preparations: USP <795> and <800>

HAZARDOUS MATERIALS 7/7/2016 OR THE RIGHT-TO-KNOW HAZARD COMMUNICATION STANDARD (HCS) DISCLAIMER

GUIDANCE FOR INDUSTRY ON FIXED DOSE COMBINATIONS (FDCs)

Application of Quality by Design (QbD) in product development. James E. Polli September 16, 2015

Guidance for Industry

Pharmacy Compounding: Infection Prevention

Table of Contents. Legal Notices... 61

Multiple stakeholders; one objective. Atypical Actives Industry Perspective. USP Excipients Stakeholder Forum November 29, 2017

FOR OFFICE USE ONLY. IACUC PROTOCOL NUMBER: IACUC Approval has been granted for the project described in this document

Profiles in CSP Insourcing: Scripps Health

STANDARD OPERATING PROCEDURES. Handling and working with Analytical Standards

Introduction regarding aggregate/particle issues in biopharmaceuticals. Yasushi Shikata Eisai Co., Ltd.

POLICY AND PROCEDURES. Office of Pharmaceutical Quality. Table of Contents

This article specifically covers incorporation of physical and chemical indicators (PCIDs) into or onto the drug product.

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN Review Article

WHO GENERAL GUIDANCE ON VARIATIONS TO MULTISOURCE PHARMACEUTICAL PRODUCTS. (February 2014)

List the names of all students authorized to conduct procedures involving animals under this proposal

Learning Objectives. What is a Compounding Pharmacist? Disclosure

General Good Compounding Practices for Nonsterile Products

High Purity Water, Buffers and Custom Solution Manufacturing Services

The biopharmaceutical industry

Guidance. Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs DRAFT GUIDANCE

1. Checklist for Grant of permission to manufacture/import of Bulk Drug already approved in the country

IV solutions that fit

ICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers

Is FMT A Drug? Lance Shea, M.S., J.D. Washington Square, Suite Connecticut Ave., NW Washington, DC, D

á232ñ ELEMENTAL IMPURITIES LIMITS

Public Assessment Report. Scientific discussion. Tranexaminezuur Sandoz 100 mg/ml, solution for injection. (tranexamic acid) NL/H/3153/001/DC

Preclinical Drug Development

Packaging of Biotech Drug Products: Challenges and Innovative Solutions. Annalisa Delnevo Research Pharma Odra Pinato SG Lab Analytics

Remote IV Compounding Validation

CLINICAL REQUIREMENTS FOR LOCALLY APPLIED, LOCALLY ACTING PRODUCTS, CONTAINING KNOWN CONSTITUENTS

Transcription:

Washington State University INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE Use of Non-Pharmaceutical Grade Substances and Compounding Drugs in Laboratory Animals Purpose: To prevent contamination, infection or damage to laboratory animals receiving drugs for research purposes, all compounds/substances/chemicals administered parenteraly should be pharmaceutical grade. To define compounding medication and outline the proper use of these drugs. This policy provides a definitive position on the use of non-pharmaceutical grade substances in the animal care and use program. The policy is consistent with the NIH/ILAR Guide for the Care and Use of Animals and the Position Statement by the Council on Accreditation, AAALAC International. This policy is also consistent with the OLAW Position Statement on the Guide for the Care and Use of Animals. Background: The use of pharmaceutical-grade substances in laboratory animals ensures that the substances administered meet established documentable standards of purity and composition. This in turn helps ensure research animal health and welfare, as well as the validity of experimental results. The use of lower grade substances/compounds with undefined or higher levels of impurities or poorly formulated non-commercial preparations can introduce unwanted experimental variables or even toxic effects, and so should be avoided if at all possible. Although pharmaceutical grade substances should be used in experimental animals whenever possible, the use of non-pharmaceutical-grade substances in experimental animals is an acceptable practice under certain circumstances. For example, in the case of new investigational compounds, they would be the only grade and formulation available. The NIH Office of Laboratory Animal Welfare (OLAW) and the United States Department of Agriculture (USDA) both have determined that the use of non-pharmaceutical grade substances should be based on: (1) Scientific necessity (2) Non-availability of an acceptable veterinary or human pharmaceutical-grade compound (3) Specific review and approval by the institutional IACUC. Cost savings alone is not considered an adequate justification for the use of non-pharmaceutical-grade substances in laboratory animals. OLAW has also stated that while the possible implications of the use of non-pharmaceutical grade substances in non-survival studies appears less evident, the scientific issues remain the same and professional judgment, as outlined above, must still apply. It is important to understand that this guideline pertains to

all components, both active and inactive, contained in the preparation to be administered. Therefore, the vehicle used to facilitate administration of a compound is as important of a consideration as the active compound in the preparation. NOTE: Some readily available commercially produced products are not pharmaceutical grade. For example, here is an excerpt from the Sigma-Aldrich statement of Terms and Conditions : Buyer's use of products Seller's products are intended primarily for laboratory research purposes and, unless otherwise stated on product labels, in Seller's catalog or in other literature furnished to Buyer, are not to be used for any other purposes, including but not limited to, in vitro diagnostic purposes, in foods, drugs, medical devices or cosmetics for humans or animals or for commercial purposes. Buyer acknowledges that the products have not been tested by Seller for safety and efficacy in food, drug, medical device, cosmetic, commercial or any other use, unless otherwise stated in Seller's literature furnished to Buyer. Definitions: Pharmaceutical grade compound: Drug, biologic, reagent, etc. which is approved by the FDA or for which a chemical purity standard has been written/established by USP/NF, BP Analytical grade bulk chemical: ~99% purity; Certificate of Analysis is usually available Non-availability: Not commercially available from an active US vendor; includes formulations supplied as tablet, capsule, injectable, etc. New investigational compound: Supplied by its manufacturer for testing in an experimental setting only and for this reason would not have chemical purity standards established; by default is considered a nonpharmaceutical grade compound USP/NF: United States Pharmacopeia/National Formulary BP: British Pharmacopeia FDA: Food and Drug Administration; FDA approved compounds are manufactured using USP/NF compounds Compounding: the combining, mixing, or alters ingredients of a drug to create a medication tailored to the needs of an individual patient. Parenteral: administered via injection or infusion. Common injection types (IV, subcutaneous (under the skin), and intramuscular (into the muscle). Policy Within the Animal Subject Approval Form (ASAF) it is necessary to define whether or not all compounds being administered to research and teaching animals are pharmaceutical grade.

To determine if compounds are pharmaceutical grade, the FDA has a reference that can be used: The Orange Book is for human FDA approved drugs http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm The Green Book is for veterinary FDA approved drugs http://www.fda.gov/animalveterinary/products/approvedanimaldrugproducts/ Pharmaceutical grade compounds occasionally may not be listed in either of these books, but will be labeled with a NDC (National Drug Code), or NADA/ANADA. When selecting compounds the following order of choice should be applied: 1. FDA-approved veterinary or human pharmaceutical substances; 2. FDA-approved veterinary or human pharmaceutical substances used to compound a needed dosage form; 3. USP/NF or BP pharmaceutical grade substance used in a needed dosage form (also includes compounded products from any source); 4. Analytical grade bulk chemical used to compound a needed dosage form (requires justification); 5. Other grades and sources of substances (requires justification). For a majority of common substances used in laboratory animal research, pharmaceutical grade (USP or NF grade) substances are available and should be used. Examples of common substances that are available in USP or NF grades include: Saline DMSO Corn oil Tamoxifen Tetracycline Analgesics (e.g., Buprenorphine) Anesthetics (e.g. Ketamine, MS 222) Euthanasia agents (e.g. Beuthanasia-D) How to determine if your substance is pharmaceutical grade: 1. Presence of an NDC (National Drug Code) number on the box, bottle, or vial (this number is often in very fine print, and may be difficult to read; however it is a reliable indicator of the substance grade); and

2. Presence of an expiration date; and 3. Presence of a lot number; and 4. Purchased from a USDA licensed vendor or pharmacy, or listed as pharmaceutical grade in the vendor catalog 5. Verbiage on box, bottle, or vial stating the product is FDA approved, or the presence of the USP insignia When developing and reviewing a proposal to use non-pharmaceutical grade substances, the investigator and IACUC should consider animal welfare and scientific issues related to the use of the substances, including potential for contamination, safety, efficacy, and the inadvertent introduction of confounding research variables. For all substance use, the IACUC should consider the grade/purity being proposed, the formulation of the final product, and issues such as sterility, pyrogenicity, stability, ph, osmolality, site/route of administration, pharmacokinetics, physiological compatibility, and quality control. The IACUC may use a variety of administrative methods to review and approve the use of such agents. For example, the IACUC may establish acceptable scientific criteria within the institution, rather than on a case-by-case basis. The use of nonpharmaceutical-grade compounds in laboratory animals shall be clearly delineated and justified in the protocol document and/or covered by an IACUC policy developed for their use. Compounding The IACUC considers dilutions/mixtures/compounding to be equivalent to pharmaceutical grade as long as all ingredients within the solution/mixture are pharmaceutical grade. Sterility and proper storage must be followed during compounding (See preparation methodologies) Expiration of pharmaceutical grade mixtures are considered expired three months from the date of preparation. All dilutions or mixtures must be labeled minimally with: o Active compounds o Concentration o Preparation date o Expiration date Compound Preparation and Storage Methodologies Compounds for injection must be prepared in a sterile manner: o Use sterile constituents o Mix solutions using sterile technique (hood, open flame, etc.) o Pass solution through a syringe filter (0.22um) at the time of preparation into a sterile container (rubber-capped glass bottle) Maintain proper storage conditions for the constituents of the solution (proper temperature and light) Discard if solution is cloudy, precipitated or discolored

REFERENCES: U.S. Department of Agriculture, Animal and Plant Health Inspection Service, Animal Care, Policy 3Veterinary Care, April 14, 1997. Frequently asked questions about the public health service policy on humane care and use of laboratory animals. Wolff A, Garnett N, Potkay S, Wigglesworth C, Doyle D, Thornton V. Lab Animal (NY). 2003 Oct; 32(9 OLAW, PHS Policy on Humane Care and Use of Laboratory Animals, December 1, 2011, Frequently asked questions, F. Animal Use and Management (4) Policy #29: Reviewed and approved by WSU IACUC: 7.29.15